↑ Rising
Business
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Novartis' experimental heart drug Pelacarsen has failed a pivotal study, surprising both the company and cardiologists.
Novartis
10 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Novartis
This hub groups 10 separate news trends connected to Novartis, spanning July 6, 2026 through September 5, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 79 article observations and 79 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
▲ Peaking
Business
🔮 fades ✓
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis's $3.2B deal with Alteogen is a surprise move that could reshape the subcutaneous drug delivery market.
◼ Archived
Business
🔮 fades ✓
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
◼ Archived
Business
🔮 holds ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.
◼ Archived
Business
🔮 fades ✓
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
◼ Archived
Business
🔮 fades ✓
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
◼ Archived
Health
🔮 fades ✓
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
Novartis’s IL‑6 blocker Pacibekitug slashes inflammation markers for half a year, sparking debate over its heart‑benefit potential.
◼ Archived
Health
🔮 fades ✓
A close look at the new cholesterol guidelines, plus the role of diet
New cholesterol guidelines are out, and they may change how you manage your heart health.
◼ Archived
Business
🔮 fades ✓
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA's rejection of ITM's radiopharma therapy sends shockwaves through the pharmaceutical industry.
◼ Archived
Business
🔮 fades ✓
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.